Eris Lifesciences Past Earnings Performance
Past criteria checks 2/6
Eris Lifesciences has been growing earnings at an average annual rate of 5.9%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 15.7% per year. Eris Lifesciences's return on equity is 12.2%, and it has net margins of 16.9%.
Key information
5.9%
Earnings growth rate
6.0%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 15.7% |
Return on equity | 12.2% |
Net Margin | 16.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22Revenue & Expenses Breakdown
How Eris Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 22,469 | 3,803 | 4,323 | 0 |
31 Mar 24 | 19,913 | 3,920 | 4,217 | 0 |
31 Dec 23 | 18,406 | 3,864 | 3,958 | 0 |
30 Sep 23 | 17,750 | 3,856 | 3,841 | 0 |
30 Jun 23 | 17,298 | 3,824 | 3,721 | 0 |
31 Mar 23 | 16,618 | 3,822 | 3,548 | 0 |
31 Dec 22 | 15,663 | 3,970 | 3,362 | 0 |
30 Sep 22 | 14,766 | 3,959 | 3,104 | 0 |
30 Jun 22 | 13,746 | 3,940 | 2,773 | 0 |
31 Mar 22 | 13,262 | 4,061 | 2,622 | 0 |
31 Dec 21 | 12,993 | 3,941 | 2,572 | 0 |
30 Sep 21 | 12,763 | 3,834 | 2,553 | 0 |
30 Jun 21 | 12,482 | 3,728 | 2,377 | 0 |
31 Mar 21 | 11,926 | 3,551 | 2,439 | 0 |
31 Dec 20 | 11,625 | 3,432 | 2,790 | 0 |
30 Sep 20 | 11,192 | 3,165 | 2,717 | 0 |
30 Jun 20 | 10,744 | 3,015 | 2,156 | 0 |
31 Mar 20 | 10,582 | 2,965 | 2,317 | 0 |
31 Dec 19 | 10,252 | 2,943 | 2,520 | 0 |
30 Sep 19 | 10,119 | 3,110 | 2,470 | 0 |
30 Jun 19 | 9,920 | 3,036 | 1,887 | 0 |
31 Mar 19 | 9,672 | 2,908 | 2,453 | 0 |
31 Dec 18 | 9,851 | 2,925 | 2,304 | 0 |
30 Sep 18 | 9,442 | 2,870 | 2,258 | 0 |
30 Jun 18 | 9,212 | 2,945 | 1,708 | 0 |
31 Mar 18 | 8,196 | 2,941 | 2,027 | 0 |
31 Dec 17 | 8,026 | 2,800 | 1,931 | 0 |
30 Sep 17 | 7,781 | 2,735 | 1,818 | 0 |
30 Jun 17 | 7,277 | 2,505 | 1,787 | 0 |
31 Mar 17 | 7,205 | 2,468 | 1,737 | 0 |
31 Mar 16 | 5,967 | 1,112 | 1,746 | 0 |
31 Mar 15 | 5,456 | 892 | 1,632 | 0 |
31 Mar 14 | 5,088 | 704 | 1,664 | 0 |
Quality Earnings: ERIS has high quality earnings.
Growing Profit Margin: ERIS's current net profit margins (16.9%) are lower than last year (22.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ERIS's earnings have grown by 5.9% per year over the past 5 years.
Accelerating Growth: ERIS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ERIS had negative earnings growth (-0.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.2%).
Return on Equity
High ROE: ERIS's Return on Equity (12.2%) is considered low.